| Dll3 binding proteins and methods of use |
2022-11-03 |
2023-1-01 |
|
| Flt3 binding proteins and methods of use |
2022-8-08 |
2022-10-01 |
|
| Extended-release immune cell engaging proteins and methods of treatment |
2022-6-24 |
2023-2-16 |
|
| Trispecific binding proteins and methods of use |
2022-6-08 |
2022-8-01 |
|
| Mesothelin binding proteins |
2022-6-06 |
2022-9-06 |
|
| Msln targeting trispecific proteins and methods of use |
2022-6-02 |
2023-2-16 |
|
| Dll3 targeting trispecific proteins and methods of use |
2022-6-02 |
2022-12-08 |
|
| Trispecific proteins and methods of use |
2022-6-02 |
2022-8-09 |
|
| Bcma targeting trispecific proteins and methods of use |
2022-6-02 |
2023-1-19 |
|
| single domain serum albumin binding protein |
2022-5-17 |
2022-8-17 |
|
| B cell maturation antigen binding proteins |
2022-4-25 |
2022-7-20 |
|
| Psma targeting tritacs and methods of use |
2022-3-31 |
2022-10-06 |
|
| Combination therapy with immune cell engaging proteins and immunomodulators |
2022-3-08 |
2022-9-15 |
|
| Single chain variable fragment cd3 binding proteins |
2022-1-24 |
2022-4-26 |
|
| Epcam binding proteins and methods of use |
2021-11-14 |
2022-1-01 |
|
| Epcam targeting trispecific protein for treatment of cancer |
2021-11-04 |
2022-5-12 |
|
| Psma targeting tritacs and methods of use |
2021-5-11 |
2021-11-18 |
|
| Prostate specific membrane antigen binding protein |
2020-12-15 |
2021-4-22 |
|
| Pro immune modulating molecule comprising a clustering moiety |
2020-11-12 |
2021-5-20 |
|
| PSMA Targeting Trispecific Proteins and Methods of Use |
2020-10-16 |
2021-4-01 |
|
| Msln targeting trispecific proteins and methods of use |
2020-2-26 |
2020-8-27 |
|
| Single chain variable fragment cd3 binding proteins |
2020-1-27 |
2020-7-23 |
|
| Single chain variable fragment CD3 binding proteins |
2020-1-27 |
2023-4-11 |
2023-4-11 |
| Conditionally activated target-binding molecules |
2019-9-20 |
2021-11-18 |
|
| Egfr binding proteins and methods of use |
2019-9-20 |
2022-1-20 |
|
| Conditionally activated binding protein comprising a sterically occluded target … |
2019-5-14 |
2019-11-21 |
|
| Conditionally active receptors |
2019-5-14 |
2020-3-26 |
|
| Dual binding moiety |
2019-5-14 |
2021-9-16 |
|
| Binding moiety for conditional activation of immunoglobulin molecules |
2019-5-14 |
2021-1-07 |
|
| triespecific proteins targeting msln and methods of use |
2018-5-11 |
2020-6-09 |
|
| MESOTHELIN BINDING PROTEINS |
2018-5-11 |
2021-11-30 |
|
| Compositions and methods for adoptive cell therapies |
2018-5-03 |
2020-4-16 |
|
| Inducible monovalent antigen binding protein |
2018-2-28 |
2020-5-14 |
|
| Targeted checkpoint inhibitors and methods of use |
2018-2-28 |
2018-9-07 |
|
| Innate immune cell inducible binding proteins and methods of use |
2018-1-19 |
2018-7-26 |
|
| Innate immune cell trispecific binding proteins and methods of use |
2017-10-13 |
2019-7-25 |
|
| Proteínas de ligação à mesotelina |
2018-5-11 |
2021-11-30 |
|